Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Thushara Pattupara"'
Autor:
Hassan Javanbakht, Henrik Mueller, Johanna Walther, Xue Zhou, Anaïs Lopez, Thushara Pattupara, Julie Blaising, Lykke Pedersen, Nanna Albæk, Malene Jackerott, Tianlai Shi, Corinne Ploix, Wouter Driessen, Robert Persson, Jacob Ravn, John A.T. Young, Søren Ottosen
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 11, Iss C, Pp 441-454 (2018)
Chronic hepatitis B infection (CHB) is an area of high unmet medical need. Current standard-of-care therapies only rarely lead to a functional cure, defined as durable hepatitis B surface antigen (HBsAg) loss following treatment. The goal for next ge
Externí odkaz:
https://doaj.org/article/1962d4b211f2443bb9955ca1ed51da8a
Autor:
Thomas Bohnacker, Dorothea Gruber, Sara Laudato, Martin Schwill, Charles-Henry Fabritius, Raquel Herrador, Katrin Westritschnig, Thushara Pattupara, Vikram Ayinampudi, Stefanie Flückiger-Mangual
Publikováno v:
Cancer Research. 83:3907-3907
Resistance to targeted therapies is a major challenge in oncology. Disease progression is caused by multiple resistance mechanisms. Besides pre-existing and acquired genetic alternations, adaptive non-mutational reprogramming as well as modulation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fe8de7e2a4c43a621952cdab9b55b3a
https://doi.org/10.1158/1538-7445.am2023-3907
https://doi.org/10.1158/1538-7445.am2023-3907
Autor:
Lykke Pedersen, Robert Persson, Corinne Ploix, Xue Zhou, John A. T. Young, Thushara Pattupara, Hassan Javanbakht, Tianlai Shi, Johanna Walther, Julie Elisabeth Françoise Blaising, Henrik Mueller, Wouter H. P. Driessen, Nanna Albæk, Jacob Ravn, Anaïs Lopez, Søren Ottosen, Malene Jackerott
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 11, Iss C, Pp 441-454 (2018)
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids
Chronic hepatitis B infection (CHB) is an area of high unmet medical need. Current standard-of-care therapies only rarely lead to a functional cure, defined as durable hepatitis B surface antigen (HBsAg) loss following treatment. The goal for next ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e7f5e083b00161c949a8777063fcc7d
https://doi.org/10.1016/j.omtn.2018.02.005
https://doi.org/10.1016/j.omtn.2018.02.005